February 10, 2008
Diabetes Drug Avandia Associated with Increased Risk of Osteoporosis
The type 2 diabetes drug Avandia, from GlaxoSmithKline (GSK), is making headlines again as scientists find that long-term use of the drug may increase the risk of osteoporosis among patients. Avandia, also referred to as rosiglitazone, was approved in June 1999, since that time the drug has been taken by millions of Americans.
The study was conducted by the Salk Institute for Biological Studies and first appeared in the scientific health journal, Nature Medicine in the Dec. 2 online issue. Researchers found that the drug may contribute to bone loss over time and that the drug may speed up the process of osteoporosis, thinning of bones and may result in bone fractures in the body that can be fatal to type 2 diabetes patients who already experience hardships from the symptoms associated with this illness.
Dangerous Avandia Side-Effects
Avandia is an oral anti-diabetic medication that has been associated with congestive heart failure, according to warnings released by the U.S. Food and Drug Administration (FDA).
In early 2007, GlaxoSmithKline reported the results of a 26-week, double blind, fixed-dose study that resulted in approximately 40 percent of patients taking Avandia to have reduced their insulin dose, compared to those receiving placebo pills. However, in November 2007, […]
Full Article At: KnowHow-Now.com Articles




















